Category: Latest News

The Resource Detectives program, developed by the Multiple Sclerosis Association of America (MSAA), provides a virtual volunteer opportunity for anyone interested in giving back to the community but unable to do so in the traditional sense of working on-site.

A thinner needle will soon be available for individuals taking Betaseron® (interferon beta-1b) for the long-term treatment of MS. The thinner needle is being offered as a way to potentially help reduce the pain and anxiety often associated with injections.

Two changes have recently been made to the labeling and prescribing information for Tysabri® (natalizumab). Manufactured and marketed by Biogen Idec and Elan, Tysabri is approved by the United States Food and Drug Administration (FDA) for the treatment of multiple sclerosis (MS) as well as Crohn’s disease.